Member-only story
Unlocking the Benefits of Continuous Patient Engagement for the Health Insurance Industry
The advancement of technology today has made the choice of the treatment care-givers and the insurers for patients quite diverse and dynamic. Episodic visits, and clients providing minimal feedback on their progress outside of regular rendezvous with their physicians or specialists, are quickly being replaced by constant or near real-time monitoring of their clients’ state by health insurers. This change from the post-symptomatic model of interaction to the pre-symptomatic one is revolutionizing the very essence of health insurers’ activity, as the latter claim that constant communication with the members is beneficial for both parties due to better health and lower expenses.
Therefore, what does the patient’s engagement mean for the health insurance industry when it is continuous? Now let us drill down into how this approach is advantageous for insurers and beneficial to patients and reduces cost at the same time.
What is Continuous Patient Engagement?
While the Continuous Patient Engagement or CBE can be defined as patient-centered care that is ongoing compared with the intermittent or sporadic contact typical of a conventional clinician–patient relationship. Using PX6 Medical Systems’ health management and BambuMeta’s wallet cards, patient support, motivation, and reminders are consistently maintained between clinical appointments closing the loop between them.
To health insurers it means that the insurers henceforth are not just cheque-book wielders who budget for their policyholders’ healthcare payments but genuine stakeholders in the policyholders’ health. Through engagement, insurers assist members in dealing with chronic illnesses , arresting a disease’s advancement, and improving wellbeing. This approach has become more vital in the recent past due to research that evidently reveals that sustained interactions not only lead to patients’ better health condition but also reduced costs related to urgent treatment (Doe et al., 2022).
